Gilead Sciences Inc - Company Profile
Powered by 
All the data and insights you need on Gilead Sciences Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Gilead Sciences Inc Strategy Report
- Understand Gilead Sciences Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
View moreGilead Sciences Catalyst Calendar
Proactively evaluate Gilead Sciences Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Gilead Sciences Catalyst Calendar data
| Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
|---|---|---|---|---|---|---|---|
| 28 Sep 2019 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
| 09 Sep 2019 | Constraining Patent Expiry (Japan) | Gilead Sciences Inc | GILD | ranolazine ER | Cardiovascular; Central Nervous System; Metabolic Disorders; Musculoskeletal Disorders | Amyotrophic Lateral Sclerosis; Atrial Fibrillation; Cardiovascular Disease; Chronic Stable Angina; Coronary Artery Disease (CAD) (Ischemic Heart Disease); Diastolic Heart Failure; Hypertrophic Cardiomyopathy; Myotonic Dystrophy; Pulmonary Hypertension; Stable Angina; Type 2 Diabetes; Vascular Dysfunction | GD Estimates |
| 01 Sep 2019 | Phase II Trial Initiation | Gilead Sciences Inc | GILD | sacituzumab govitecan | Oncology | Endometrial Cancer; Head And Neck Cancer Squamous Cell Carcinoma; Hepatocellular Carcinoma; Non-Small Cell Lung Cancer; Small-Cell Lung Cancer; Solid Tumor | Clinical Trial Registry |
| 01 Sep 2019 | Phase IV Trial Initiation | Azienda Ospedaliera Policlinico di Modena; Gilead Sciences Inc; University of Modena and Reggio Emilia | GILD | (bictegravir sodium + emtricitabine + tenofovir alafenamide) | Infectious Disease | Human Immunodeficiency Virus (HIV) Infections (AIDS) | Clinical Trial Registry |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer